The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C

Oncogene

Volumn 31, Issue 6, 2012, Pages 776-786

  Niu, X ^a   Zhang, T ^a   Liao, L ^a   Zhou, L ^a   Lindner, D J ^b   Zhou, M ^a   Rini, B ^b   Yan, Q ^c   Yang, H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

gene expression; hypoxia inducible factor; JARID1C KDM5C SMCX; trimethyl H3K4; von Hippel Lindau

Indexed keywords

DENSITY ENHANCED PHOSPHATASE 1; GROWTH DIFFERENTIATION FACTOR 15; HISTONE DEMETHYLASE; HISTONE H3; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROTEIN; PROTEIN COL6A1; PROTEIN DNAJC12; PROTEIN JARID1B; PROTEIN JARID1C; RETINOBLASTOMA BINDING PROTEIN 2; SHORT HAIRPIN RNA; SOMATOMEDIN BINDING PROTEIN 3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CARCINOMA CELL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SUBUNIT; TUMOR XENOGRAFT;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE VI; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KIDNEY NEOPLASMS; LYSINE; METHYLATION; MICE; MICE, NUDE; MUTATION; OXIDOREDUCTASES, N-DEMETHYLATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84856955226     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.266     Document Type: Article

References (46)

1. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973. (Pubitemid 26382753)
2. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837. (Pubitemid 46802390)
3. Berrios M, Osheroff N, Fisher PA. (1985). In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82: 4142-4146. (Pubitemid 15053599)
4. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. (2008). The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283: 36542-36552.
5. Cheung I, Shulha HP, Jiang Y, Matevossian A, Wang J, Weng ZP et al. (2010). Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci USA 107: 8824-8829.
6. Dalgliesh GL, Furge K, Greenman C, Chen LN, Bignell G, Butler A et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
7. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K et al. (1999). Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914. (Pubitemid 29158534)
8. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54. (Pubitemid 32972036)
9. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. (2003). Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115: 565-576. (Pubitemid 37506045)
10. Iliopoulos O, Kibel A, Gray S, Kaelin Jr WG. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
11. Isaacs JS, Jung YJ, Neckers L. (2004). Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1 alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 279: 16128-16135. (Pubitemid 38509304)
12. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K et al. (2002). Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99: 13459-13464. (Pubitemid 35215403)
13. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M et al. (2001). HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468. (Pubitemid 32335941)
14. Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH et al. (2007). The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128: 1077-1088. (Pubitemid 46437259)
15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472. (Pubitemid 32335942)
16. Kaelin Jr WG. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682. (Pubitemid 37328918)
17. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O et al. (1999). Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284: 657-661. (Pubitemid 29289593)
18. Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P et al. (2007). The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 128: 889-900. (Pubitemid 46341416)
19. Kondo K, Kim WY, Lechpammer M, Kaelin Jr WG. (2003). Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83.
20. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246. (Pubitemid 41039148)
21. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. (2010). Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 30: 344-353.
22. Li N, Carrel L. (2008). Escape from X chromosome inactivation is an intrinsic property of the Jarid1c locus. Proc Natl Acad Sci USA 105: 17055-17060.
23. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P et al. (2004). Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10: 6282S-6289S. (Pubitemid 39287479)
24. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275. (Pubitemid 29246458)
25. Mersman DP, Du HN, Fingerman IM, South PF, Briggs SD. (2009). Polyubiquitination of the demethylase Jhd2 controls histone methylation and gene expression. Genes Dev 23: 951-962.
26. Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH et al. (2008). The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol 28: 2701-2717. (Pubitemid 351542369)
27. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O et al. (2006). Clusterin is a secreted marker for a hypoxiainducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168: 574-584. (Pubitemid 43271155)
28. Negrotto S, Hu ZB, Alcazar O, Ng KP, Triozzi P, Lindner D et al. (2011). Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res 71: 1431-1441.
29. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE et al. (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
30. Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ et al. (2008). Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 416: 387-394.
31. Rini BI, Sosman JA, Motzer RJ. (2005). Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96: 286-290. (Pubitemid 41097667)
32. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
33. Schraml P, Frew IJ, Thoma CR, Boysen G, Struckmann K, Krek W et al. (2009). Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod Pathol 22: 31-36.
34. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. (Pubitemid 37328811)
35. Semenza GL. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007: cm8.
36. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH et al. (1997). Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51: 553-555. (Pubitemid 27088174)
37. Sharma SV, Lee DY, Li BH, Quinlan MP, Takahashi F, Maheswaran S et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
38. Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F et al. (2007). The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 447: 601-605. (Pubitemid 46868038)
39. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P et al. (2009). VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11: 994-1001.
40. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK et al. (2008). Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 372: 892-897.
41. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS et al. (2009). Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106: 4260-4265.
42. Yan Q, Bartz S, Mao M, Li L, Kaelin Jr WG. (2007). The hypoxiainducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 27: 2092-2102. (Pubitemid 46418467)
43. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X et al. (2007). pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27. (Pubitemid 47531976)
44. Zhang HF, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI et al. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420. (Pubitemid 46670080)
45. Zhou X, Sun H, Chen HB, Zavadil J, Kluz T, Arita A et al. (2010). Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res 70: 4214-4221.
46. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. (2004). Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol Cancer Res 2: 89-95. (Pubitemid 38250425)